Daiichi Sankyo: Steering a Global Organization Custom Case Solution & Analysis

Evidence Brief: Daiichi Sankyo Global Steering

1. Financial Metrics

Revenue Targets: The 5-Year Business Plan (FY2021–FY2025) targets 1.6 trillion JPY in revenue by 2025 (Source: Exhibit 1).
Oncology Contribution: Oncology revenue is projected to reach 600 billion JPY by FY2025, representing approximately 37.5 percent of total sales (Source: Paragraph 4).
R&D Investment: Total R&D spending allocated for the five-year period ending 2025 is 1.5 trillion JPY (Source: Exhibit 5).
AstraZeneca Collaboration: The 2019 deal for Enhertu included a 1.35 billion USD upfront payment and up to 6.9 billion USD in total potential value (Source: Paragraph 12).
Profitability: Operating profit margin target for FY2025 is set at 25 percent or higher (Source: Exhibit 1).

2. Operational Facts

Product Focus: The strategy centers on the 3-ADC (Antibody-Drug Conjugate) pipeline: Enhertu, Dato-DXd, and HER3-DXd (Source: Paragraph 8).
Geographic Footprint: Headquarters remain in Tokyo, with major commercial and clinical hubs in Basking Ridge, New Jersey, and Munich, Germany (Source: Paragraph 15).
R&D Structure: Shifted from a traditional therapeutic area model to a Global Specialty Unit (GSU) structure to accelerate oncology development (Source: Paragraph 18).
Manufacturing: Complex ADC production requires three distinct stages: monoclonal antibody production, payload/linker synthesis, and conjugation (Source: Paragraph 22).

3. Stakeholder Positions

Sunao Manabe (CEO): Advocates for a Global One Management model to break down silos between Japan and the rest of the world (Source: Paragraph 6).
Ken Takeshita (Global Head of R&D): Focused on integrating Japanese laboratory excellence with Western clinical trial speed (Source: Paragraph 20).
Global Oncology Leadership: Often located in the US, pushing for faster decision-making and market-competitive compensation structures (Source: Paragraph 24).
Japanese Parent Employees: Express concerns regarding the loss of corporate identity and the speed of organizational change (Source: Paragraph 27).

4. Information Gaps

Post-2025 Pipeline: The case lacks detailed data on the early-stage pipeline beyond the current ADC platform.
Margin Compression: Specific data on how the profit-sharing agreement with AstraZeneca affects net margins per unit sold is absent.
Talent Turnover: No specific attrition rates provided for the US-based oncology team following the restructuring.

Strategic Analysis

1. Core Strategic Question

How can Daiichi Sankyo transition from a Japan-centric primary care company to a global oncology leader without losing its R&D heritage or failing to compete for Western talent?
Can the organization resolve the friction between Tokyo-based centralized control and the decentralized agility required by the US pharmaceutical market?

2. Structural Analysis

Value Chain Analysis: The competitive advantage resides in the DXd ADC technology platform. However, the value chain is bifurcated: R&D occurs largely in Japan, while clinical development and commercialization are centered in the US. This creates a geographic and cultural gap at the most critical hand-off point in the drug lifecycle.

7-S Framework Lens: There is a fundamental misalignment between Strategy (Global Oncology) and Shared Values (Traditional Japanese Management). The current Structure (Matrix) is struggling to reconcile these differences, leading to slowed decision-making in a sector where speed is the primary currency.

3. Strategic Options

Option	Rationale	Trade-offs
Full Oncology Autonomy	Relocate Oncology HQ to the US with full P&L authority.	Maximizes speed and talent retention; risks alienating the Japanese parent and creating a company within a company.
Functional Global Integration	Unified global heads for R&D, Commercial, and Supply Chain regardless of geography.	Ensures consistency; requires a massive cultural shift and high-speed digital communication infrastructure.
Regional Partnership Model	Continue heavy reliance on partners like AstraZeneca for non-Japanese markets.	Reduces risk and capital expenditure; cedes long-term capability building and significant profit share.

4. Preliminary Recommendation

Daiichi Sankyo must pursue Functional Global Integration. The company cannot afford to remain a Japanese firm with overseas branches; it must become a global entity that happens to be headquartered in Tokyo. This requires moving the global leads for Oncology functions to the markets where those functions are most critical (primarily the US), while maintaining the core chemistry and biologics expertise in Japan.

Implementation Roadmap

1. Critical Path

Month 1-3: Finalize the Global One Management reporting lines. Every functional head must have a single global P&L responsibility.
Month 3-6: Implement a global compensation framework. Oncology talent in New Jersey and Munich cannot be tied to Tokyo-based salary scales if the company intends to compete with big pharma.
Month 6-12: Standardize the ADC manufacturing hand-off. Create a cross-functional team between Japanese production and US clinical teams to reduce cycle times for trial supplies.

2. Key Constraints

Cultural Friction: The Japanese seniority system (Nenko) conflicts with the meritocratic, high-stakes environment of US biotech. This will cause internal tension during promotions.
Communication Latency: The 13-to-14-hour time difference between Tokyo and the US East Coast is a physical barrier to the agile decision-making required for clinical trial adjustments.

3. Risk-Adjusted Implementation Strategy

To mitigate the risk of talent flight, the company should establish a dual-leadership transition period. For the first 12 months, Japanese incumbents and newly appointed global leads will co-manage key workstreams. This prevents a total loss of institutional knowledge while signaling the shift to a global model. Success will be measured by the speed of patient enrollment in Phase 3 trials for Dato-DXd and the stability of the US commercial leadership team.

Executive Review and BLUF

1. BLUF

Daiichi Sankyo must aggressively shift its center of gravity toward the US market to secure its future as an oncology powerhouse. The current technical lead provided by the Enhertu platform is a temporary window that will close as competitors catch up. Organizational reform is the only way to sustain this advantage. The company must move beyond its Japanese-centric management roots and adopt a global functional model that prioritizes speed, market-competitive incentives, and decentralized clinical decision-making. Failure to do so will result in becoming a mere R&D boutique for larger partners like AstraZeneca.

2. Dangerous Assumption

The analysis assumes that the technical superiority of the DXd ADC platform is sufficient to overcome structural organizational inefficiencies. In the pharmaceutical industry, a superior drug can still fail commercially if the clinical development is slow or if the commercial execution is hampered by centralized, distant leadership.

3. Unaddressed Risks

Partner Dependency: Over-reliance on AstraZeneca for commercialization in key markets limits the ability of Daiichi Sankyo to build its own global commercial muscle, potentially leaving the firm hollowed out once the current patents expire.
Regulatory Divergence: Increasing friction between US FDA and international regulatory bodies may require more localized autonomy than a Global One Management model typically allows.

4. Unconsidered Alternative

The team did not fully explore a Spin-off Strategy. Separating the Oncology business into a standalone global entity (potentially IPO-ing in the US) would provide the currency (stock options) and the agility needed to compete with Merck and Roche, while allowing the Japanese parent to focus on its traditional strengths and domestic market.